SCHEMBL3537657

SCHEMBL3537657

CCN1CCN(c2ccc3nc(-c4n[nH]c5cc(OC)c(OC)cc45)n(C)c3c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 1/20 0.46
FGFR1 P11362 7/20 0.46
FGFR2 P21802 5/20 0.46
CDK4 P11802 1/20 0.42
CCNA2 P20248 1/20 0.42
CCND1 P24385 1/20 0.42
CDK2 P24941 1/20 0.42
CCND3 P30281 1/20 0.42
ABL1 P00519 1/20 0.42
LRRK2 Q5S007 2/20 0.40
FGFR3 P22607 1/20 0.40
KDR P35968 1/20 0.40
NR1I2 O75469 1/20 0.40
ADRB1 P08588 1/20 0.40
HTR1A P08908 1/20 0.40
ADRA2A P08913 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
DRD2 P14416 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3533624 0.91 ABL1 (0.55) PRKDCFGFR1FGFR2ABL1NR1I2
SCHEMBL3536967 0.87 ABL1 (0.52) FGFR1FGFR2ABL1KHKFLT1
SCHEMBL3544838 0.85 ABL1 (0.53) FGFR1FGFR2ABL1LRRK2DRD2
SCHEMBL3539745 0.85 PRKDC (0.41) PRKDCFGFR1FGFR2CDK4CCNA2
SCHEMBL3612553 0.85 ABL1 (0.51) FGFR1FGFR2ABL1LRRK2FGFR3
SCHEMBL3538529 0.84 FGFR1 (0.51) FGFR1FGFR2CDK4CCNA2CCND1
SCHEMBL3538866 0.84 FGFR1 (0.51) FGFR1FGFR2CDK4CCNA2CCND1
SCHEMBL3536581 0.83 ABL1 (0.52) FGFR1FGFR2ABL1LRRK2FGFR3
SCHEMBL3536833 0.81 FGFR1 (0.48) FGFR1FGFR2CDK4CCNA2CCND1
SCHEMBL3534853 0.81 FGFR1 (0.48) FGFR1FGFR2CDK2HTR1ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK PRKDC 50/4885FGFR1 886/4885FGFR2 1236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.